Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients. / Ostrowski, Sisse R; Katzenstein, Terese L; Piironen, Timo; Gerstoft, Jan; Pedersen, Bente K; Ullum, Henrik.
In: J A I D S, Vol. 35, No. 4, 2004, p. 337-42.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients
AU - Ostrowski, Sisse R
AU - Katzenstein, Terese L
AU - Piironen, Timo
AU - Gerstoft, Jan
AU - Pedersen, Bente K
AU - Ullum, Henrik
PY - 2004
Y1 - 2004
N2 - High blood levels of the soluble urokinase receptor (suPAR) strongly predict increased mortality in human immunodeficiency virus-1 (HIV-1)-infected patients. This study investigated the plasma concentration of suPAR in 29 treatment-naive HIV-1-infected patients during 5 years treatment with highly active antiretroviral therapy (HAART). Plasma suPAR decreased after introducing HAART, most pronounced during the first treatment year. The change in plasma suPAR was independent of changes in viral replication and CD4+ cells but it was strongly correlated with plasma levels of the soluble TNF receptor II. Compared with healthy individuals, plasma suPAR and sTN-FrII was increased in untreated patients. After initiating HAART, plasma sTNFrII remained increased whereas plasma suPAR decreased to a level comparable with healthy individuals. The present data indicate that the circulating suPAR level is linked to inflammation in untreated as well as HAART-treated HIV-1-infected patients.
AB - High blood levels of the soluble urokinase receptor (suPAR) strongly predict increased mortality in human immunodeficiency virus-1 (HIV-1)-infected patients. This study investigated the plasma concentration of suPAR in 29 treatment-naive HIV-1-infected patients during 5 years treatment with highly active antiretroviral therapy (HAART). Plasma suPAR decreased after introducing HAART, most pronounced during the first treatment year. The change in plasma suPAR was independent of changes in viral replication and CD4+ cells but it was strongly correlated with plasma levels of the soluble TNF receptor II. Compared with healthy individuals, plasma suPAR and sTN-FrII was increased in untreated patients. After initiating HAART, plasma sTNFrII remained increased whereas plasma suPAR decreased to a level comparable with healthy individuals. The present data indicate that the circulating suPAR level is linked to inflammation in untreated as well as HAART-treated HIV-1-infected patients.
KW - Adult
KW - Antiretroviral Therapy, Highly Active
KW - CD4 Lymphocyte Count
KW - Cohort Studies
KW - Drug Administration Schedule
KW - Female
KW - HIV Infections
KW - HIV-1
KW - Humans
KW - Male
KW - Receptors, Cell Surface
KW - Receptors, Tumor Necrosis Factor, Type II
KW - Receptors, Urokinase Plasminogen Activator
KW - Viral Load
M3 - Journal article
C2 - 15097149
VL - 35
SP - 337
EP - 342
JO - J A I D S
JF - J A I D S
SN - 1525-4135
IS - 4
ER -
ID: 36144393